Sanofi India (500674) Q1 2026 earnings summary

Executive summary

• Unaudited financial results for the quarter ended March 31, 2026, were approved by the Board of Directors.

• Insulin portfolio achieved double-digit growth both year-over-year and sequentially, marking strong performance in the domestic market.

• Strategic partnerships in Cardiovascular, Oral anti-diabetes, and CNS segments have strengthened the business foundation.

• Export sales are stabilizing despite ongoing geopolitical challenges.

• Operational excellence and efficiency improvements continue through targeted market initiatives.

Significant events and developments

• Tenure of two Independent Directors, Mr. Aditya Narayan and Mrs. Usha Thorat, completed as of April 29, 2026.

• Mr. Rahul Bhatnagar appointed as Chairman of the Board effective April 30, 2026.

• Board reconstituted key committees, including Audit, Nomination and Remuneration, Stakeholders Relationship, Risk Management, and CSR Committees, with new leadership and memberships effective April 30, 2026.

Segment performance

• Insulin portfolio delivered 14% sequential growth and 19% year-over-year growth, maintaining leadership in the diabetes injectable segment.

• Strategic partnerships in other therapeutic areas are expected to catalyze further growth and market penetration.